I 
115TH CONGRESS 
1ST SESSION H. R. 1854 
To require the use of prescription drug monitoring programs and to facilitate 
information sharing among States. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 3, 2017 
Mr. JENKINS of West Virginia (for himself and Mr. RYAN of Ohio) introduced 
the following bill; which was referred to the Committee on Energy and 
Commerce, and in addition to the Committee on the Judiciary, for a pe-
riod to be subsequently determined by the Speaker, in each case for con-
sideration of such provisions as fall within the jurisdiction of the com-
mittee concerned 
A BILL 
To require the use of prescription drug monitoring programs 
and to facilitate information sharing among States. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Prescription Drug 
Monitoring Act of 2017’’. 
SEC. 2. DEFINITIONS. 
In this Act: 
VerDate Sep 11 2014 
02:08 Apr 08, 2017
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1854.IH
H1854
lotter on DSK5VPTVN1PROD with BILLS
(1) 
CONTROLLED
SUBSTANCE.—The 
term 
‘‘controlled substance’’ has the meaning given the 
term in section 102 of the Controlled Substances 
Act (21 U.S.C. 802). 
(2) COVERED
STATE.—The term ‘‘covered 
State’’ means a State that receives funding under 
the Harold Rogers Prescription Drug Monitoring 
Program established under the Departments of 
Commerce, Justice, and State, the Judiciary, and 
Related Agencies Appropriations Act, 2002 (Public 
Law 107–77; 115 Stat. 748) or the controlled sub-
stance monitoring program under section 399O of 
the Public Health Service Act (42 U.S.C. 280g–3). 
(3) DISPENSER.—The term ‘‘dispenser’’— 
(A) means person licensed or otherwise au-
thorized by a State to deliver a prescription 
drug product to a patient or an agent of the pa-
tient; and 
(B) does not include a person involved in 
oversight or payment for prescription drugs. 
(4) PDMP.—The term ‘‘PDMP’’ means a pre-
scription drug monitoring program. 
(5) PRACTITIONER.—The term ‘‘practitioner’’ 
means a practitioner registered under section 303(f) 
of the Controlled Substances Act (21 U.S.C. 823(f)) 
VerDate Sep 11 2014 
02:08 Apr 08, 2017
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H1854.IH
H1854
lotter on DSK5VPTVN1PROD with BILLS
to prescribe, administer, or dispense controlled sub-
stances. 
(6) STATE.—The term ‘‘State’’ means each of 
the several States and the District of Columbia. 
SEC. 3. PRESCRIPTION DRUG MONITORING PROGRAM RE-
QUIREMENTS. 
(a) IN GENERAL.—Beginning 2 years after the date 
of enactment of this Act, each covered State shall re-
quire— 
(1) each prescribing practitioner within the cov-
ered State or their designee, who shall be licensed or 
registered healthcare professionals or other employ-
ees who report directly to the practitioner, to consult 
the PDMP of the covered State before initiating 
treatment with a prescription for a controlled sub-
stance listed in schedule II, III, or IV of section 
202(c) of the Controlled Substances Act (21 U.S.C. 
812(c)), and every 3 months thereafter as long as 
the treatment continues; 
(2) the PDMP of the covered State to provide 
proactive notification to a practitioner when patterns 
indicative of controlled substance misuse, including 
opioid misuse, are detected; 
(3) each dispenser within the covered State to 
report each prescription for a controlled substance 
VerDate Sep 11 2014 
02:08 Apr 08, 2017
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1854.IH
H1854
lotter on DSK5VPTVN1PROD with BILLS